Scenic Biotech, a Netherlands-based leader in modifier therapies for severe diseases, has signed a license and research agreement with American biopharmaceutical company Alnylam Pharmaceuticals to leverage its Cell-Seq platform for discovering novel targets for RNAi therapeutics.

Scenic’s Cell-Seq platform enables high-resolution mapping of modifier genes for novel target discovery.  

"Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets," said Vincent Blomen, Senior Director of Discovery Sciences at Scenic Biotech.

"As we advance our pipeline of first-in-class disease-modifying therapies, we're committed to empowering our partners in developing innovative medicines for patients facing devastating conditions,” he added.

It is Scenic's third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb.

These collaborations harness the Cell-Seq platform's capacity to deliver genetic insights that drive novel therapeutic discovery and development. While Scenic focuses primarily on identifying modifier genes, the technology has proven its ability to map unexplored biological pathways and investigate disease mechanisms.